Natera’s (NTRA) Outperform Rating Reaffirmed at Sanford C. Bernstein

Natera (NASDAQ:NTRA)‘s stock had its “outperform” rating restated by Sanford C. Bernstein in a research note issued to investors on Friday,Benzinga reports. They presently have a $310.00 price target on the medical research company’s stock. Sanford C. Bernstein’s target price would suggest a potential upside of 19.42% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. JPMorgan Chase & Co. raised their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Piper Sandler restated an “overweight” rating and issued a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. Finally, Evercore reaffirmed an “outperform” rating and set a $270.00 target price on shares of Natera in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $259.22.

Natera Price Performance

Shares of NTRA opened at $259.58 on Friday. Natera has a 12 month low of $131.81 and a 12 month high of $271.47. The stock’s 50-day moving average is $211.64 and its two-hundred day moving average is $215.54. The stock has a market cap of $37.17 billion, a PE ratio of -161.01 and a beta of 1.56.

Insider Activity at Natera

In other news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 162,342 shares of company stock worth $35,283,396. 5.05% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Natera

Several institutional investors have recently bought and sold shares of the stock. Reflection Asset Management bought a new stake in shares of Natera during the 4th quarter worth $29,000. Palladiem LLC purchased a new position in Natera in the 4th quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in shares of Natera during the third quarter valued at approximately $32,000. International Assets Investment Management LLC raised its stake in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust lifted its holdings in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.